Creation of a Biospecimen Repository from Patients with ANCA-associated Vasculitis

Overview

About this study

The purpose of this study is to develop a repository of serum and urine samples from patients with AAV to support future studies into the development of such biomarkers. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Any patient with a diagnosis of AAV.
  • Potential subjects will be identified on the basis of their being scheduled for evaluation in the pulmonary vasculitis clinic.
  • All patients scheduled in the clinic will be recruited, either in advance of their appointment (via telephone contact or posted written materials) or at the time of their clinical visit (via a face-to-face meeting). 
  • Community outreach will not be feasible for this rare disease, but again, all patients scheduled in the pulmonary vasculitis clinic are eligible for recruitment. 
  • Patients admitted to the hospital with a diagnosis of AAV are also eligible for participation.  
  • Informed consent will be obtained via usual verbal and written procedures in the clinic itself.  Consent will be obtained by clinical research personnel.

For disease controls of interest

Inclusion Criteria:

  • Diagnosis of interstitial lung disease (ILD), autoimmune renal disease, or rheumatologic condition.
  • Willingness and ability to complete blood draws.

Exclusion Criteria:

  • Age <18.

For healthy controls

Inclusion Criteria:

  • Male or female, age 18 to 85.
  • Willingness and ability to complete blood draws.

Exclusion Criteria:

  • History of or currently have an autoimmune disease.
  • History of diagnosis and treatment for cancer within the last 5 years except for non-melanoma skin cancers or breast or genitourinary cancer in situ.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 6/25/2024. Questions regarding updates should be directed to the study team contact.
 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Ulrich Specks, M.D.

Closed-enrolling by invitation

What is this? (?)
"Close"
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Michael Stachowitz

(507) 284-4862

Stachowitz.Michael@mayo.edu

More information

Publications

Publications are currently not available